Clinical trial · no report yet · Phase 3
MANGROVE
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
- NCT04002297 ↗
- Active not recruiting
- BeOne Medicines
- 25 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 14 | |
| Podcasts | 10 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
- Interventions
- zanubrutinib; bendamustine; rituximab
- Arms
- Arm A: zanubrutinib plus rituximab · Experimental
- Arm B: bendamustine plus rituximab · Active comparator
- Enrollment
- 510
- Primary outcomes
- Progression-free survival (PFS) determined by independent central review
- Sponsor
- BeOne Medicines
- Start
- Aug 20, 2019
- Primary completion
- Apr 27, 2026
- Results posted
- No
- Registry record
- NCT04002297 · updated Sep 30, 2026
Publications
linked from the registry- Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021 Jan;17(3):255-262. doi: 10.2217/fon-2020-0794. Epub 2020 Sep 28. PubMed 32985902